FINWIRES · TerminalLIVE
FINWIRES

Illumina Launches Whole Genome Cancer Research Workflow

By

Illumina (ILMN) said Thursday it launched a whole-genome sequencing research workflow for molecular residual disease detection and opened early access to select clinical research partners.

The company said the workflow is expected to support residual disease detection and cancer genomic profiling using solid tumor and blood samples.

Illumina said the workflow can complete processing in about five days and targets analytical sensitivity down to 10 parts per million for certain tumors.

The company said its Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise.

Illumina said it plans a broader commercial launch next year and is developing an additional workflow designed to support lower detection thresholds using NovaSeq X systems.

Price: $153.98, Change: $+3.81, Percent Change: +2.54%

Related Articles

Wire

Dell Technologies Unit Wins $9.69 Billion US Navy Contract

Dell Technologies (DELL) unit Dell Federal Systems won a blanket purchase agreement with an overall estimated value of $9.69 billion from the US Navy under the Department of Defense Enterprise Software Initiative.The agreement will streamline software acquisition across the Defense Department, the intelligence community, and the US Coast Guard, according to a statement.The deal will allow clients to procure Microsoft (MSFT) software licenses, cloud subscriptions, and Software Assurance, according to the Department.

$DELL$MSFT
Wire

Dave to Replace American Woodmark in S&P SmallCap 600

Dave (DAVE) is set to replace American Woodmark (AMWD) in the S&P SmallCap 600 before trading begins Monday, S&P Dow Jones Indices said.MasterBrand (MBC) is acquiring American Woodmark in a deal expected to close May 29, the S&P Global (SPGI) unit said Wednesday in a statement.Dave shares rose 4.2% in after-hours trading.

$AMWD$DAVE$SPGI
Wire

Citi Trends Reports Preliminary Fiscal Q1 Sales, Lifts FY Comparable-Store Sales Outlook

Citi Trends (CTRN) reported fiscal Q1 preliminary sales late Wednesday of $230.9 million and raised its full-year outlook for comparable-store sales growth.A year earlier, sales were $201.7 million.Comparable-store sales growth in fiscal 2026 is expected to range from 8% to 10%, compared with the prior 5% to 7% forecast, the company said.Citi Trends also lifted its full-year adjusted EBITDA guidance to $35 million to $40 million from the previous outlook of $34 million to $38 million.Citi Trends shares rose 10% in after-hours trading.

$CTRN